Whalesbook
### Vaidya 2.0: A New Contender in Healthcare AI
Fractal Analytics has launched Vaidya 2.0, the latest iteration of its healthcare reasoning model, signaling a strategic push into the burgeoning AI healthcare sector. The company announced that Vaidya 2.0 achieved a score of 50.1 on OpenAI's HealthBench (hard) benchmark, reportedly making it the first AI model to surpass the 50-point threshold on this challenging evaluation. Fractal claims this performance outstrips that of OpenAI's own GPT-5 and Google's Gemini Pro 3, positioning Vaidya 2.0 as a potent tool for healthcare operating system workflows [cite:Scraped News]. The model is designed to bridge the gap between complex healthcare data and actionable insights, with envisioned applications including Emergency Assist for triage, Symptom Checker for initial guidance, and Patient Journey Assist for end-to-end patient support. Its capabilities extend to powering Doctor Assist functions and administrative tasks, showing strong performance on the MedExpert benchmark as well [cite:Scraped News].
### Post-IPO Recovery and Analyst Optimism Fuel Gains
The market's reaction to Vaidya 2.0's announcement provided a much-needed boost to Fractal Analytics' stock, which had experienced a subdued debut. Shares listed on February 16, 2026, at a discount to their IPO price, with trading on the NSE opening at ₹876 against an issue price of ₹900, and closing lower. However, by February 19, 2026, the stock was trading around ₹887.75, reflecting a recovery. This turnaround has been significantly influenced by positive analyst sentiment. Prabhudas Lilladher (PL) Capital initiated coverage on Fractal Analytics with a 'Buy' rating and a target price of ₹1,260 per share. This target implies a potential upside of approximately 40% from the IPO price, based on a valuation of 22 times FY28E EV/EBITDA. PL Capital cited the company's strong account mining capabilities, steady growth in top accounts, low dependence on new logos, and favorable positioning in AI and revenue growth management as key drivers. The company recently raised ₹2,840.16 crore through its IPO, which was subscribed 2.66 times.
The Hedge Fund View: Execution Risks and Competitive Pressures
Despite the optimistic analyst outlook and the impressive benchmark performance of Vaidya 2.0, significant headwinds persist. The AI healthcare sector is intensely competitive, with tech giants like OpenAI and Google continuously advancing their models. While Vaidya 2.0 claims to outperform competitors on specific benchmarks like HealthBench (hard), the true test lies in its real-world clinical utility and seamless integration into complex healthcare systems beyond controlled evaluations. The gap between benchmark scores and actual patient outcomes or operational efficiencies is a critical factor. Fractal Analytics' valuation, with a market capitalization around ₹15,000-15,500 crore and P/E ratios hovering between 65x-110x based on FY25/FY26 earnings, appears ambitious, especially considering its recent weak listing. Furthermore, reliance on a few top clients (54.2% of revenue from top 10 clients for Fractal.ai in H1 FY26) and substantial dependence on the US market (64.9% of revenue in H1 FY26) present concentration risks. The company also faces the challenge of translating its innovative AI capabilities into consistent profitability, with management aiming to lift EBITDA margins beyond 20% from current levels.
### Future Trajectory and Market Dynamics
Fractal Analytics' alignment with the ₹10,300 crore India AI Mission and its showcase at the India AI Impact Summit 2026 underscore its strategic importance within national AI initiatives [cite:Scraped News]. The broader artificial intelligence in healthcare market is projected for substantial growth, with estimates ranging from $86.8 billion by 2030 to over $500 billion by 2033, driven by demand for enhanced efficiency and better patient outcomes. PL Capital anticipates consolidated USD revenue CAGR of 19.3% and INR EBITDA CAGR of 30.9% over FY26E–FY28E, supported by operating leverage and a richer mix from higher-margin SaaS businesses under its Fractal Alpha segment. The success of this strategy will hinge on Fractal's ability to not only innovate its AI models but also to effectively deploy and monetize them in a demanding and highly regulated healthcare environment, turning benchmark victories into sustained market leadership.